MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
There is considerable evidence that antidepressants, particularly serotonin uptake inhibitors, are effective in the treatment of panic disorder (PD). Monoamine oxidase inhibitors (MAOI) may also have beneficial effects in PD. In this study 30 patients with PD with or without agoraphobia (DSM-III-R) were treated with the selective and reversible MAO-A inhibitor brofaromine (150 mg daily) in a 12-week double-blind placebo controlled design. A clinical relevant improvement was found in more than 70% of the patients treated with brofaromine, whereas no significant improvement was observed on placebo. After an increase in anxiety in the first week, a clinically relevant improvement in anxiety symptoms was found, followed by a subsequent reduction in agoraphobic avoidance in patients treated with brofaromine. A similar improvement was observed on distress scores related to panic attacks, although there was no significant reduction in the number of panic attacks. The most prominent side-effects were middle sleep disturbance and nausea. No increase in blood pressure was observed. During a follow-up period of another 12 weeks a further improvement was found in patients treated with brofaromine.
van Vliet
I M
IM
Department of Biological Psychiatry, Academic Hospital Utrecht, The Netherlands.
Westenberg
H G
HG
Den Boer
J A
JA
D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D005239:Fear / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016584:Panic Disorder / Q000188:drug therapy* / Q000523:psychology; D010880:Piperidines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine